医学
对比度(视觉)
药代动力学
造影剂
神经组阅片室
放射科
超声波
碘
介入放射学
核医学
内科学
计算机科学
材料科学
神经学
人工智能
精神科
冶金
作者
Aart J. van der Molen,Ilona A. Dekkers,Remy W. F. Geenen,Marie‐France Bellin,Michele Bertolotto,Torkel B. Brismar,Jean-Michel Corréas,Gertraud Heinz-Peer,Andreas H. Mahnken,Carlo Cosimo Quattrocchi,Alexander Radbruch,Peter Reimer,Giles Roditi,Laura Romanini,Carmen Sebastià,Fulvio Stacul,C Olivier
标识
DOI:10.1007/s00330-023-10085-5
摘要
The pharmacokinetics of contrast media (CM) will determine how long safe waiting intervals between successive CT or MRI examinations should be. The Contrast Media Safety Committee has reviewed the data on pharmacokinetics of contrast media to suggest safe waiting intervals between successive contrast-enhanced imaging studies in relation to the renal function of the patient. CLINICAL RELEVANCE STATEMENT: Consider a waiting time between elective contrast-enhanced CT and (coronary) angiography with successive iodine-based contrast media administrations in patients with normal renal function (eGFR > 60 mL/min/1.73 m2) of optimally 12 h (near complete clearance of the previously administered iodine-based contrast media) and minimally 4 h (if clinical indication requires rapid follow-up). KEY POINTS: • Pharmacokinetics of contrast media will guide safe waiting times between successive administrations. • Safe waiting times increase with increasing renal insufficiency. • Iodine-based contrast media influence MRI signal intensities and gadolinium-based contrast agents influence CT attenuation.
科研通智能强力驱动
Strongly Powered by AbleSci AI